The incidence rate and mortality of hepatocellular carcinoma are still very high. Surgery, ablation therapy, and liver transplantation are crucial in the treatment of liver cancer, but they are prone to recurrence after surgery; In addition, hepatocellular carcinoma is often diagnosed in advanced stages, which makes systemic therapy, especially immunotherapy, an important treatment option. The immune microenvironment of liver cancer has immunosuppressive effects, and overcoming immunosuppression is the key to immunotherapy for the liver cancer. In recent years, multiple clinical trials have shown that immunotherapy, especially the combination of immune checkpoint inhibitors, has better efficacy and survival rates, making it the gold standard for treating patients with advanced hepatocellular carcinoma. This success has prompted research to expand the application of immunotherapy to neoadjuvant, adjuvant, and conversion therapies, as well as patients with liver dysfunction and those awaiting liver transplantation. Although its efficacy has been proven, there are still a large number of patients who develop resistance to immunotherapy, which requires various innovative strategies to address this challenge.

The incidence rate and mortality of hepatocellular carcinoma are still very high. Surgery, ablation therapy, and liver transplantation are crucial in the treatment of liver cancer, but they are prone to recurrence after surgery; In addition, hepatocellular carcinoma is often diagnosed in advanced stages, which makes systemic therapy, especially immunotherapy, an important treatment option. The immune microenvironment of liver cancer has immunosuppressive effects, and overcoming immunosuppression is the key to immunotherapy for the liver cancer. In recent years, multiple clinical trials have shown that immunotherapy, especially the combination of immune checkpoint inhibitors, has better efficacy and survival rates, making it the gold standard for treating patients with advanced hepatocellular carcinoma. This success has prompted research to expand the application of immunotherapy to neoadjuvant, adjuvant, and conversion therapies, as well as patients with liver dysfunction and those awaiting liver transplantation. Although its efficacy has been proven, there are still a large number of patients who develop resistance to immunotherapy, which requires various innovative strategies to address this challenge.

The rapid development of second-generation sequencing technology and bioinformatics has enabled us to find out more about the components of the microbiome throughout the respiratory tract,including bacteria,fungi and viruses.A growing number of studies have shown that there is a close relationship between respiratory microorganisms and various respiratory diseases,which provides new areas of research relating to asthma,cystic fibrosis (CF),chronic obstructive pulmonary disease (COPD),lung cancer and influenza.In this paper,research progress in respiratory microbiome (bacteria, fungi and viruses)and related diseases is reviewed.

Objective To provide theoretical reference for clinical therapy of pulmonary adenocarcinoma by evaluating the effects of polysaccharides and pioglitazone on mouse model of pulmonary adenocarcinoma and to explore the relationship between inflammation and pulmonary adenocarcinoma. Methods One hundred mice were averagely divided into five groups, including control group, model group, polysaccharides group, pioglitazone group, polysaccharides and pioglitazone group (unite group). Polysaccharides solution (500 mg/kg) was given to polysaccharides group, pioglitazone solution (15 mg/kg) was given to pioglitazone group, polysaccharides solution (500 mg/kg) and pioglitazone solution (15 mg/kg) were given to unite group;and the equal volume of saline (10 mL/kg) was given to control and model group (1 t/d, 5 d/w, continuously 20 w ). The pulmonary adenocarcinoma induced by urethane was evaluated in each group at different time points. The levels of NF-κB, TNF-α, IL-1β and IL-6 were measured in each group at the 12th week and the 20th week respectively. Results The body weights were increased in the control group, which were decreased in other groups during urethane-injection, but increased continuously after the injection. At the 20th week, nodules were found in lung surfaces in all mice except mice of control group. The lung index was higher in all mice except mice of control group. The levels of NF-κB, TNF-α, IL-1βand IL-6 were significantly higher at 12th week and 20th in model group, polysaccharides group, pioglitazone group, polysaccha?rides and pioglitazone group than those of control group. The levels of NF-κB, TNF-α, IL-1βand IL-6 were significantly lower in polysaccharides group, pioglitazone group, polysaccharides and pioglitazone group than those of model group. Con?clusion Sustained inflammatory response is one of the risk factors for the development of lung adenocarcinoma. Polysaccha?rides and pioglitazone can reduce the level of inflammation in mouse lung adenocarcinoma, suggesting that both of them can be used as potential adjuvant in the clinical treatment of lung adenocarcinoma.